Portal de investigación
PAUTA DE DOSIFICACIÓN AJUSTABLE DE BRODALUMAB EN COMPARACIÓN CON EL TRATAMIENTO ESTÁNDAR CON BRODALUMAB DURANTE 52 SEMANAS EN PACIENTES CON PSORIASIS EN PLACAS DE MODERADA A GRAVE Y ?120 KG DE PESO CORPORAL; ADJUST.
Datos básicos
- Protocolo:
- LP0160-1329
- EUDRACT:
- 2017-004998-13
- NCT:
- Centro:
- HOSPITAL DE MANISES
- Año de incio:
- 2020
- Año de finalización:
- 2025
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
LEO PHARMA A/S
Resultados del Ensayo Clínico
[Translated article] Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer - Basal Cell Carcinoma or Squamous Cell Carcinoma - Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study.
Minano Medrano, R.; (...); Garcia-Doval, I
Article. 10.1016/j.ad.2022.01.035. 2022
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
Daudén E; (...); Llamas-Velasco M
Article. 10.1111/ijd.16915. 2024
Epigenetic characterization of the inflammatory hidradenitis suppurativa phenotype
Martorell, Antonio; (...); Sandoval, Juan
Meeting Abstract. 2023
Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer -Basal Cell Carcinoma or Squamous Cell Carcinoma-Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study.
Miñano Medrano R; (...); García-Doval I
Article. 10.1016/j.ad.2022.01.003. 2022
Safety and Efficacy Profile of Bimekizumab in Patients With Psoriasis and Psoriatic Arthritis: An 18-Patient Case Series.
Melgosa Ramos, F J; (...); Martorell, A
Article. 10.1016/j.ad.2024.08.009. 2024